| RETA Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the RETA shares outstanding history going back to 5/26/2016:
Also see: RETA Market Cap History RETA YTD Return |
RETA Shares Outstanding History — Reata Pharmaceuticals Share Count Over Time
As of 8/1/2023 Reata Pharmaceuticals has 33.50 million RETA shares outstanding. Investors often track the RETA shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows RETA share count trends over time, with 30 historical shares outstanding datapoints presented, dating back to 5/26/2016.
| RETA Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RETA Historical Shares Outstanding: +29.06% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RETA Stock Price Chart |
| About Reata Pharmaceuticals Inc |
| Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. Co. focuses on therapeutics for the treatment of diseases with few or no approved therapies. Co.'s main programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease. Co.'s primary product candidates include bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich's ataxia. Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. We show 30 historical shares outstanding datapoints in our coverage of RETA's shares outstanding history. Understanding the changing numbers of RETA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like RETA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching RETA by allowing them to research RETA shares outstanding history as well as any other stock in our coverage universe. |
| RETA Current Stock Quote |
Quotes delayed 20 minutes  Free RETA Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| RETA Share Performance |
| Shares Outstanding Peers |
| Reata Pharmaceuticals (RETA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
REXN Shares Outstanding History RGEN Shares Outstanding History RGLS Shares Outstanding History RGNX Shares Outstanding History RIGL Shares Outstanding History RKTO Shares Outstanding History RLAY Shares Outstanding History RLMD Shares Outstanding History RLYB Shares Outstanding History RMD Shares Outstanding History More Healthcare companies » |
RETA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
